{name}
{subtitle}
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~11 mi. (Milan, Italy, +147 more cities)
facility
Istituto Europeo di Oncologia ( Site 0536)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~11 mi. (Milan, Italy, +140 more cities)
facility
ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 0331)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~11 mi. (Milan, Italy, +130 more cities)
facility
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0353)
drug
BCG solution, +1 more drug
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
city
~11 mi. (Milan, Italy, +131 more cities)
facility
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1610)
drug
CAPOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~11 mi. (Milan, Italy, +127 more cities)
facility
Ospedale San Raffaele IRCCS /ID# 214311
drug
azacitidine, +2 more drugs
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
city
~11 mi. (Milan, Italy, +30 more cities)
facility
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0802)
drug
MK-1308A, +4 more drugs